Dr Junyun Lai
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
25 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8 T cells in lymph nodes
DOI: 10.1038/s41590-026-02419-42026
Journal article
Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancer
DOI: 10.1016/j.ejps.2025.1073592025
Journal article
Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors
DOI: 10.1038/s41467-025-59021-92025
Journal article
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
DOI: 10.1038/s41586-025-09212-72023
Research grants (other domestic)
Development of Next Generation CRISPR/Cas9 Engineered Chimeric Antigen Receptor T Cells for the Effective Treatment of Breast Cancer
2022
Research grants (ARC, NHMRC, MRFF)
Engineering Chimeric Antigen Receptor (CAR) T Cells That Induce Host Antitumour Immunity
2021
Research grants (international)
Enhancing CAR T Cell Therapy of Solid Cancers by Engaging the Host Immune System
RECENT SCHOLARLY WORKS
2024
Journal article
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
DOI: 10.1038/s41586-024-07242-12023
Journal article
A2AR eGFP reporter mouse enables elucidation of A2AR expression dynamics during anti-tumor immune responses
DOI: 10.1038/s41467-023-42734-02023
Journal article
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity
DOI: 10.1016/j.celrep.2023.1130142023
Journal article
Single-cell protein expression profiling resolves circulating and resident memory T cell diversity across tissues and infection contexts
DOI: 10.1016/j.immuni.2023.06.0052023
Journal article
CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance
DOI: 10.1016/j.xcrm.2023.1009172022
Journal article
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses
DOI: 10.1016/j.ccell.2022.09.007